Skip to main content
Premium Trial:

Request an Annual Quote

ABI Shuffles Executives, Creates New Positions in Reorganization Effort

NEW YORK, April 17 – As part of an effort to restructure its business units, Applied Biosystems has created two new vice president positions and promoted a third executive, the company said Tuesday.

The company named Stephen Lombardi to the position of vice president for a new division entitled applications and products and Robert Jones as vice president for its platform products research and development division.

Additionally, Applied Biosystems of Foster City, Calif., promoted Carolyn Martin, formerly the senior director of North American sales, to succeed Lombardi as vice president of field operations for the Americas.

Lombardi, who had formerly served as vice president for Applied’s field operations in the Americas, will oversee the marketing of the company’s product lines and will lead a new service aspect of the company. Jones, who was vice president and general manager of the company’s informatics division, will oversee all instrument and software development projects. 

Michael Hunkapiller, president of Applied Biosystems, said in a statement that these changes were the result of a company restructuring effort that had been in the works for months.

The company’s previous structure, Hunkapiller said, “was implemented in simpler times in which each of our major products was designed for one primary application that had little overlap with those of other products.” Now, he said, the platforms can be used for a variety of applications.

"Over the past several months our senior management team has been evaluating the impact of these issues, particularly in terms of whether changes in our business unit alignments could assist us in meeting our business goals,” Hunkapiller said. “This new organization is the result of that evaluation process. It positions us well for the future, and I am very pleased that three experienced members of our management team will be assuming these important new roles in our company."  

Applied Biosystems was not immediately available for comment.  
The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.